BIOHEART-B (02185) announced that the Iberis® multi-electrode renal artery radiofrequency ablation catheter system (Iberis® RDN system), developed by its subsidiary Shanghai Antong Medical Technology Co., Ltd., has recently obtained registration in Vietnam. This registration was achieved with joint support from Biosensors International Group, Ltd. and Antong. Antong and Biosensors have entered into a strategic partnership for the commercialization of the Iberis® RDN system, with collaboration covering multiple regions including, but not limited to, EU countries, Asia-Pacific, and Latin America (LATAM). As of the date of this announcement, the Iberis® RDN system is the only renal denervation (RDN) product globally approved for use via both the transradial approach (TRA) and transfemoral approach (TFA). TRA enhances the safety, efficacy, and cost-effectiveness of RDN procedures. The company's ultimate goal is to provide outpatient RDN surgery for patients worldwide. Antong previously obtained CE marking for the Iberis® RDN system in Europe in 2016.